Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.22
- Piotroski Score 7.00
- Grade Buy
- Symbol (ALKS)
- Company Alkermes plc
- Price $27.69
- Changes Percentage (-0.79%)
- Change -$0.22
- Day Low $27.49
- Day High $28.18
- Year High $32.88
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $36.50
- High Stock Price Target $50.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.36
- Trailing P/E Ratio 7.12
- Forward P/E Ratio 7.12
- P/E Growth 7.12
- Net Income $355.76 M
Income Statement
Quarterly
Annual
Latest News of ALKS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Chaotic Sydney train shutdown averted after eleventh hour crisis talks with union
Sydney's train network narrowly avoided a shutdown as the government agreed to run 24-hour services, meeting rail union demands. Talks led to the strike being called off, averting disruptions to all t...
By The Guardian | 16 hours ago -
At UN climate talks, a draft of the deal gives little clarity on climate cash for developing nations
A draft text released at COP29 climate talks in Baku lacks specifics on how much wealthy nations will contribute to climate finance, causing concern among negotiators. The need for progress and transp...
By AP NEWS | 16 hours ago -
Gwen Stefani talks about the impact of Blake Shelton's love
55-year-old singer Gwen Stefani discussed her reflections on her life and love journey on The Drew Barrymore Show. She shared how love with Blake Shelton inspired her latest album "Bouquet" and emphas...
By Newsweek | 1 day ago
